Selected article for: "amino acid and bind ability"
Author: Courtney Mycroft-West; Dunhao Su; Stefano Elli; Scott Guimond; Gavin Miller; Jeremy Turnbull; Edwin Yates; Marco Guerrini; David Fernig; Marcelo Lima; Mark Skidmore
Title: The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 Receptor Binding Domain undergoes conformational change upon heparin binding
  • Document date: 2020_3_2
    • ID: 0d77ojnb_24
    Snippet: Studying SARS-CoV-2 Spike protein structure and behaviour in solution is a vital step for the development of effective therapeutics against SARS-CoV-2. Here, the ability of the SARS-CoV-2 S1 RBD to bind pharmaceutical heparin has been studied using spectroscopic techniques in concert with molecular modelling. The data show that SARS-CoV-2 S1 RBD binds to heparin and that upon binding, a significant structural change is induced. Moreover, moieties.....
    Document: Studying SARS-CoV-2 Spike protein structure and behaviour in solution is a vital step for the development of effective therapeutics against SARS-CoV-2. Here, the ability of the SARS-CoV-2 S1 RBD to bind pharmaceutical heparin has been studied using spectroscopic techniques in concert with molecular modelling. The data show that SARS-CoV-2 S1 RBD binds to heparin and that upon binding, a significant structural change is induced. Moreover, moieties of basic amino acid residues, known to constitute heparin binding domains, are solvent accessible on the SARS-CoV-2 S1 RBD surface and form a continuous patch that is suitable for heparin binding.

    Search related documents:
    Co phrase search for related documents
    • amino acid and effective therapeutic: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • amino acid and molecular modelling: 1, 2, 3, 4, 5, 6
    • amino acid and protein structure: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • amino acid and RBD surface: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • amino acid and SARS effective therapeutic: 1, 2, 3
    • amino acid residue and bind domain: 1, 2
    • amino acid residue and protein structure: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • amino acid residue and RBD surface: 1
    • bind domain and effective therapeutic: 1
    • bind domain and protein structure: 1, 2, 3
    • bind domain and RBD surface: 1
    • effective therapeutic and heparin bind: 1, 2
    • effective therapeutic and molecular modelling: 1
    • effective therapeutic and protein structure: 1, 2, 3, 4, 5, 6
    • effective therapeutic and RBD surface: 1
    • effective therapeutic and SARS effective therapeutic: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • effective therapeutic and SARS effective therapeutic development: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • molecular modelling and protein structure: 1, 2, 3, 4, 5, 6
    • molecular modelling and SARS effective therapeutic: 1